Gout: Supplements for Uric Acid and Flare Prevention

Evidence-based supplement guidance for gout management, including uric acid lowering and flare prevention. Learn which supplements have research support and when to seek medical care.

When to see a doctor / red flags

Seek immediate medical attention if you experience:

• Sudden severe joint pain (especially in the big toe, but also ankle, knee, wrist) with warmth, swelling, and redness
• Fever accompanying joint pain (suggests possible infection or severe flare)
• Multiple joints affected or symptoms lasting more than 10 days without diagnosis
• Recurrent attacks more than twice per year
• Known gout but pain or swelling in a new joint location (may indicate tophaceous gout or other arthropathy)

Gout is a crystal-deposition arthritis caused by monosodium urate crystal precipitation in joints and surrounding tissues. It requires medical diagnosis (via joint aspiration, imaging, or clinical criteria) and often prescription urate-lowering therapy. Supplements alone do not treat acute flares and should never delay or replace anti-inflammatory medication (NSAIDs, colchicine, corticosteroids) or urate-lowering drugs (allopurinol, febuxostat, benzbromarone). Untreated or inadequately managed gout progresses to chronic tophaceous arthritis, kidney stones, and progressive joint damage.

What's happening: brief overview of gout

Gout occurs when serum uric acid (the end product of purine metabolism) exceeds saturation, forming crystals that deposit in joints and surrounding soft tissue. Triggers include purine-rich foods (red meat, seafood, high-fructose corn syrup), alcohol (especially beer), dehydration, rapid weight loss, certain medications (diuretics, low-dose aspirin), and genetic predisposition (URAT1 and other urate-handling genes).

Acute flares involve intense inflammatory response—neutrophil infiltration, IL-1β release, complement activation—causing severe pain, erythema, and swelling. Urate-lowering therapy aims to maintain serum urate <6 mg/dL (the saturation point), preventing crystal formation and allowing existing deposits to dissolve. Between flares, prophylaxis with low-dose colchicine or NSAIDs reduces flare frequency while urate-lowering medication takes effect.

Approximately 4% of US adults have gout, with higher prevalence in men, those over 40, and people with metabolic syndrome, chronic kidney disease, or diuretic use.

Supplement evidence at a glance

Supplements with strongest evidence

Cherry extract

What it does: Cherry extract contains anthocyanins and other polyphenols that inhibit xanthine oxidase (the enzyme producing uric acid) and suppress IL-1β, the key inflammatory cytokine in acute gout flares.

Evidence base: A small 2011 RCT of 10 patients and a 2012 observational study of 633 gout patients both found that cherry consumption (fresh or extract equivalent ~200 mg polyphenol daily) was associated with lower flare risk and modestly lower serum urate (reduction ~0.5 mg/dL in observational cohort). A 2022 meta-analysis of 4 observational studies found cherry intake correlated with lower gout incidence, though no large RCTs confirm causation. The evidence is promising but modest in effect size.

Typical dose: 200–500 mg cherry extract (polyphenol-standardized) daily, or equivalent to ~1 cup fresh cherries daily. Some brands standardize to 10–12% anthocyanins.

Key cautions: Cherry extracts are generally well-tolerated. High doses (>600 mg daily) may cause loose stools. Do not use as monotherapy for acute flares or instead of allopurinol in chronic prophylaxis. Safe in pregnancy at dietary doses.

Vitamin C (ascorbic acid)

What it does: Vitamin C enhances urinary uric acid excretion by reducing reabsorption in the proximal tubule and may inhibit xanthine oxidase.

Evidence base: A 2009 prospective cohort (Health Professionals Follow-Up Study, n=46,994 men) showed that vitamin C intake ≥500 mg daily was associated with ~16% lower gout risk over 20 years. A small 2010 RCT (n=40, 8 weeks) found 500 mg vitamin C daily reduced serum urate by ~0.5 mg/dL more than placebo. A 2016 systematic review noted consistent observational associations but limited RCT data. Effect is modest and develops over weeks; not suitable for acute flare treatment.

Typical dose: 500–1000 mg daily in divided doses (vitamin C absorption plateaus at 200 mg per dose). Most studies used 500 mg once or twice daily.

Key cautions: High-dose vitamin C (>2000 mg daily) increases urinary oxalate and may raise kidney stone risk, especially in men with history of stones or those with genetic oxalate disorders. Avoid high doses in G6PD deficiency. Do not rely on vitamin C monotherapy; use with allopurinol or febuxostat.

Supplements with moderate evidence

Magnesium

What it does: Magnesium is a cofactor for xanthine oxidase and may modulate uric acid synthesis; it also has anti-inflammatory properties.

Evidence base: A small 2015 RCT (n=52, 12 weeks) found that magnesium glycinate 400 mg daily reduced serum urate by ~0.7 mg/dL and flare frequency compared to placebo, but the study was open-label and sample size modest. A 2020 cross-sectional study found lower serum magnesium correlated with higher urate. No large, blinded RCTs in gout populations exist. The mechanism is plausible but evidence is weak.

Typical dose: 300–400 mg daily, preferably in an absorbed form (glycinate, malate, citrate) to avoid laxative effects.

Key cautions: High doses (>400 mg daily from supplements) may cause diarrhea. Magnesium is renally cleared; use caution if eGFR <30. Check for interactions with bisphosphonates, fluoroquinolones, and some antiarrhythmics.

Folic acid

What it does: Folic acid is a cofactor for enzymes in purine metabolism and may reduce xanthine oxidase activity.

Evidence base: A 2008 RCT (n=60) found that 5 mg folic acid daily (started before allopurinol therapy) reduced allopurinol-induced hypersensitivity reactions and modestly improved urate lowering, but was not tested as monotherapy. A small 2014 study suggested high-dose folic acid (5 mg daily × 3 months) may assist xanthine oxidase inhibitors but data are sparse and inconsistent. Folic acid is not an independent urate-lowering agent.

Typical dose: 1–5 mg daily if used adjunctively; no established independent dose for gout.

Key cautions: High-dose folic acid (>5 mg daily) may mask vitamin B12 deficiency and can interfere with antiepileptic drugs. Use only as adjunct to prescription urate-lowering therapy under physician oversight.

Supplements that don't have evidence (or are risky)

Ginger: Ginger is a potent anti-inflammatory (inhibits NF-κB and IL-1β in vitro) and is well-tolerated, but no clinical trials exist in gout patients. Its effect on uric acid metabolism is unknown. Ginger may interact with anticoagulants and NSAIDs (used in gout flares) and may cause gastrointestinal upset at high doses. Consider ginger only as adjunctive to prescription therapy for general anti-inflammatory effect, not as urate-lowering treatment.

Turmeric (curcumin): Curcumin powerfully suppresses IL-1β, NF-κB, and TNF-α in animal and cell models—mechanism theoretically suited to gout. However, no RCTs in gout populations exist. Curcumin bioavailability is poor unless paired with black pepper (piperine); typical dose 500–2000 mg daily. Risk of gastrointestinal upset and potential interaction with warfarin at high doses. Insufficient evidence to recommend in gout; may be considered off-label alongside (not instead of) allopurinol in future study.

Bromelain: A proteolytic enzyme from pineapple stem with anti-inflammatory activity in other conditions (sinusitis, arthritis), bromelain has never been tested in gout. Typical dose 500–2000 mg daily; may cause gastrointestinal upset and allergic reactions in those with pineapple allergy. Do not use as monotherapy for gout.

Lifestyle factors that often outperform supplements

Weight loss (if overweight): Obesity increases serum urate via enhanced de novo purine synthesis. A loss of 5–10% body weight can reduce urate by 0.5–1.5 mg/dL and flare frequency, rivaling some pharmaceutical interventions. Gradual weight loss via caloric restriction and exercise is preferred (rapid weight loss paradoxically triggers flares via mobilization of urate stores).

Purine restriction: Limiting red meat, organ meats, certain seafood (anchovies, sardines, mussels, scallops), and high-fructose corn syrup intake can lower serum urate by 0.5–1 mg/dL. A low-purine diet does not eliminate gout in most patients (endogenous purine synthesis often dominates) but supports pharmacotherapy.

Hydration: Drinking ≥2 L water daily enhances urinary uric acid excretion and reduces flare risk. Adequate hydration is first-line non-pharmacological prevention.

Alcohol moderation: Alcohol, especially beer (high in guanosine), increases urate production and reduces excretion. Limiting to ≤1 drink daily for women, ≤2 for men, or abstaining is strongly associated with flare prevention. Even moderate reduction (stopping binge drinking) can lower urate by 0.5+ mg/dL.

Avoid diuretics if possible: Thiazide diuretics and loop diuretics increase serum urate; ACE inhibitors or calcium-channel blockers are preferred antihypertensive agents in gout.

Putting it together: a starter framework

First: Confirm diagnosis and establish baseline serum urate with your physician. Gout diagnosis requires crystal visualization (needle-shaped, negatively birefringent monosodium urate crystals in synovial fluid) or clinical criteria plus imaging. Serum urate, 24-hour urinary urate, and renal function guide therapy choice.

Step 1 – Acute flare management (do not delay): NSAIDs (e.g., indomethacin, naproxen) or colchicine reduce pain and inflammation. High-dose corticosteroids (oral or intra-articular) are alternatives if NSAIDs/colchicine are contraindicated. Supplements have no role in acute flares.

Step 2 – Urate-lowering therapy (started after acute flare resolves): Most patients require allopurinol (typically 100–300 mg daily, titrated by serum urate response) or febuxostat (40–80 mg daily). Losartan or calcium-channel blockers provide modest additional urate lowering if needed. Goal serum urate is <6 mg/dL (or <5 mg/dL in tophaceous gout).

Step 3 – Prophylaxis during urate-lowering initiation: Low-dose colchicine (0.5–1 mg daily) or NSAID for 3–6 months prevents flares as urate deposits dissolve. Do not start urate-lowering therapy without prophylaxis.

Step 4 – Adjunctive supplements (optional, after diagnosis and prescription therapy): If serum urate remains mildly elevated (6–7 mg/dL) despite allopurinol at target dose, consider adding:

• Cherry extract 200–500 mg daily (moderate evidence, minimal interactions)
• Vitamin C 500–1000 mg daily if no kidney stone history (moderate evidence)
• Magnesium 300–400 mg daily if serum magnesium is low (weak evidence)

Step 5 – Lifestyle anchor (parallel to all above): Weight loss, hydration, purine restriction, and alcohol moderation should run alongside medication and supplements. These often prevent recurrence better than supplements alone and cost nothing.

Red flag: If flares continue despite adequate serum urate suppression (<6 mg/dL) and prophylaxis, ask your doctor about IL-1 inhibitors (canakinumab, anakinra). These are prescription biologic agents, not supplements, and are highly effective in refractory gout.

The bottom line

Gout is a serious crystal arthropathy requiring medical diagnosis, prescription urate-lowering therapy, and lifelong monitoring. Supplements like cherry extract and vitamin C show modest evidence for supporting (not replacing) allopurinol or febuxostat, and lifestyle changes—weight loss, hydration, dietary purine reduction, alcohol avoidance—are often equally or more powerful. Do not delay seeing a rheumatologist or internist to start supplements. If you are already on urate-lowering medication and are interested in adjunctive support, cherry extract or vitamin C are reasonable, low-risk options to discuss with your provider.